Thiocyanate is a heme peroxidase substrate that scavenges oxidants produced during inflammation and regulates host defense. In cystic fibrosis (CF) patients, increased airway thiocyanate levels are associated with improved lung function. Research on airway thiocyanate is limited, however, because convenient non-invasive airway sampling methods, such as exhaled breath condensate (EBC), yield low concentrations that are difficult to detect with available assays. In the present study, we developed a method for the determination of thiocyanate in dilute samples using isotope dilution headspace gas chromatography-coupled high-resolution, accurate-mass mass spectrometry (GC-HRMS). The method reliably quantified as little as 4 pmol thiocyanate in EBC and could detect even lower amounts. We successfully measured thiocyanate in EBC from seven healthy donors, with a mean ± SD of 27 ± 16 nM and a median inter-assay coefficient of variation of 10.4% over six months. The method was applied to other biological fluids (plasma from the same visit as EBC donation; bronchoalveolar lavage fluid [BALF] from infants with CF; and healthy adult mouse BALF), giving reliable quantification of samples ranging from 10 nM to 100 µM. Thiocyanate concentrations in fluids besides EBC were (from lowest to highest): 0.73 ± 0.39 µM in BALF of healthy adult mice (n = 6); 1.4 ± 1.4 µM in BALF from infants with CF (n = 24); 46 ± 22 µM in the plasma of adult volunteers (n = 7). These results demonstrate the utility of this new method for clinical determination of thiocyanate in EBC and other biological fluids.
Introduction

Thiocyanate ([SCN]
-) is a pseudohalide ubiquitously found in humans. Thiocyanate scavenges strong heme peroxidase-derived oxidants produced during inflammation (such as hypochlorous acid) and replaces them with the weaker oxidant, hypothiocyanous acid [1] . This prevents irreversible oxidation reactions with cellular macromolecules, diverting oxidation reactions to readily repairable thiols and selenols [2] . Thiocyanate concentrations in body fluids are increased by multiple environmental factors, including vegan diet and smoking [3, 4] . The effects of thiocyanate on health have been studied with regard to host defense [5] [6] [7] [8] , inflammation [9] [10] [11] , and thyroid function [3, 12, 13] . Thiocyanate is a substrate of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) anion channel [14] . Thiocyanate flux is diminished in CF airway epithelia compared to non-CF, inhibiting bacterial killing by CF cells [15, 16] . These observations led to the hypothesis that low thiocyanate may contribute to CF airways disease. Steady-state thiocyanate is decreased in the airways of CFTR knockout mice [17] and airway flux is decreased in newborn delF508 CFTR piglets [8] . However, steady-state concentrations in human clinical samples have shown mixed results. Thiocyanate was lower in CF saliva than healthy control saliva [4] , higher than disease controls in CF infant bronchoalveolar lavage fluid (BALF) [18] and similar to healthy controls in nasal turbinate lining fluid [8] . However, thiocyanate in CF nasal turbinate lining fluid was also associated with better lung function [8] . Thus, the role of thiocyanate in CF lung health merits continued study.
Opportunities to follow these studies up and explore new questions are limited by a lack of methods sensitive enough to measure thiocyanate in non-invasive airway samples. Although thiocyanate is relatively abundant in BALF, bronchoscopy is an invasive procedure most often used in pulmonary exacerbations, though prospective BALF collection efforts in CF are ongoing [19, 20] . In contrast, exhaled breath condensate (EBC) is a widely available non-invasive airway sample, but distillation of water vapor with exhaled breath aerosols dilutes the sample considerably [21, 22] . Nevertheless, several non-volatile analytes have been observed in EBC [23] . However, we are not aware of any previously published methods to measure thiocyanate in EBC.
To develop such a method, we used gas chromatography coupled to Orbitrap high-resolution, accurate-mass mass spectrometry (GC-HRMS) to measure thiocyanate derivatized with triethyloxonium tetra-
, forming the volatile ethyl thiocyanate (EtSCN). Heating promotes partitioning of EtSCN into headspace, which is injected into the GC. This method was previously developed to measure thiocyanate in saliva, which is replete with the pseudohalide (mM concentrations) [1, 24] . With Orbitrap mass spectrometry, we observed considerably lower background signal, which enhanced assay sensitivity and enabled reliable measurement of nM concentrations of thiocyanate in EBC. Application to other biological fluids showed that the method is useful in other clinical samples, including BALF. Increased assay sensitivity allowed considerable dilution of more concentrated samples such as plasma, minimizing sample consumption. with an insulated aluminum sleeve pre-cooled to − 80°C. The RTube was used to prevent salivary contamination of the EBC sample. Approximately 2 ml of EBC was collected and stored at − 80°C as 0.5 ml aliquots. For seven of these donors, platelet-poor plasma samples were also obtained by antecubital venipuncture. Briefly, 1 ml of blood was transferred into K 2 -EDTA purple top vacutainers (Beckton-Dickinson, Franklin Lakes, NJ, USA). Platelet-poor plasma was prepared by centrifuging blood at 400g for 10 min at 4°C, and the first supernatant centrifuged again at 3000g x 10 min at 4°C. Aliquots of the second (platelet-poor) supernatant were stored at − 80°C until analysis. Fasting and smoking status for EBC and plasma samples was unknown.
Methods
Chemicals and reagents
Cystic fibrosis patients
Twenty-five right middle lobe BALF samples (pooled from the second and third instilled fractions sterile saline, 1 ml/kg body weight) were collected under general anesthesia during bronchoscopy at Erasmus MC (Rotterdam, The Netherlands) from 12-to 38-month-old CF infants (Erasmus MC IRB protocol NL49725.078.14). Cell-free BALF was isolated by collecting the supernatant after centrifugation at 330g at 4°C for 5 min. BALF supernatants were stored at − 80°C prior to analysis. Patients were fasted overnight prior to the BAL procedure.
Mice
BALF samples from six male C57BL6 mice were a generous gift from Brian J. Day at National Jewish Health (Denver, CO). Ethical use of mice in research was approved by the National Jewish Health Institutional Care and Use Committee. BAL was acquired from terminally anesthetized mice by whole lung lavage with two 0.75 ml fractions of ice-cold phosphate buffer instilled intratracheally, and recovered with minimal dwell time. Cell-free BALF was isolated by centrifuging BAL at 2000 g at 4°C for 8 min. Mouse BALF supernatants were stored at − 80°C prior to analysis.
Sample derivatization
Thiocyanate was converted to the volatile EtSCN by the method of Ammazzini and co-workers [24] -. This method was previously reported to yield 64% EtSCN after aqueous reaction [25] . In this method, a stable isotopically labeled internal stan-
is added prior to derivatization, which protects against the potential for variations in reaction efficiency [24] . A sui- 
Gas chromatography coupled to mass spectrometry
Our method was adapted for Orbitrap MS from the quadrupole MSbased method of Ammazini and co-workers [24] . Gas chromatography coupled to high-resolution, accurate-mass mass spectrometry (GC-HRMS) was carried out using a Q Exactive GC Orbitrap with a TriPlus RSH autosampler interfaced to a Trace 1310 GC (Thermo Scientific, Waltham, MA, USA). Prior to each daily analytical run, the MS was multi-ion calibrated for mass accuracy and tuned to the 69 Da fragment ion of perfluorotributylamine mass calibrant gas; this fragment ion was relevant to the assay scan range of 50-100 m/z. Vials were incubated at 80°C with intermittent horizontal shaking for 10 min, then 2.5 ml headspace was withdrawn by a headspace syringe held at 80°C. Samples were injected into a split/splitless inlet with a 4 × 6.3 × 78.5 mm split liner with quartz wool installed. The inlet was held at 200°C with helium flow at 1 ml/min with a 5:1 split. After injection, the syringe was flushed with nitrogen for 20 s. EtSCN was chromatographically resolved using ultra-high purity helium maintained at a constant flow of 1 ml/min through a 30 m DB-624 column (0.25 mm inner diameter with 1.40 µm 6% cyanopropyl-phenyl, 94% dimethyl polysiloxane coating) with the following thermal gradient: 2 min hold at 60°C, 15°C/min ramp to 200°C, 30°C/min ramp to 250°C, 2 min hold (total run time of 15 min). The transfer line temperature was set to 260°C and the source to 250°C. The filament was delayed for the first 3 min of run time. Compounds were ionized in positive electron ionization at + 70 eV. The Orbitrap MS scan range was set to 50-100 m/z at 60,000 full width at half maximum resolution (200 m/z basis) and an automatic gain control target of 10 6 ions. An air blank was periodically injected during each run to ensure there was no carryover. Calibration was achieved by fitting a straight line to the peak area ratio of analytical standards and internal standard.
Statistical analysis
Chromatographic peak areas were integrated using Thermo Xcalibur Qual Browser (v. 4.0.27.19). Data were maintained in Office Excel for Mac 2016 (Microsoft, Redmond, WA, USA) and statistical analyses were performed using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). Data plots were generated using the R package 'ggplot2' v.2.2.1 [26] . Data are presented as mean ± standard deviation.
Results
High-resolution, accurate-mass mass spectrometry detection of ethyl thiocyanate
The mass spectrum of EtSCN derived from a 100 µM thiocyanate standard of natural isotopic composition (Fig. 1 + was more abundant than the molecular ion and free from interference at HRMS resolution, this product ion was selected for primary quantification of thiocyanate.
Analytical validation and optimization
Carryover was not observed when an air blank was injected between samples, and no signal was detected in any samples tested lacking Et 3 (Fig. 3A-B) . This enabled quantification of both low-and high-abundance samples. ), which we established as a procedural limit of detection (LOD). Signals for both molecular and fragment ions were reproducibly recovered starting at 4 pmol, which we established as the lower limit of quantification (LLOQ).
We also tested the response of the internal standard in multiple biological matrices. We assessed the peak area of 500 nM [S 13 C 15 N] -spiked into water, EBC, plasma and human and mouse BALF ( Supplementary Fig. 2 ). The coefficient of variation (CV) of [HS 13 C 15 N] + area was ≤ 20% in all matrices (mean = 17.8 ± 2.4%).
Peak area means did not significantly differ (Kruskal-Wallis H-test, p = 0.69). Therefore, we concluded that the biological matrices were not likely to confound internal standard-based quantification by GC-HRMS.
Quantification of thiocyanate in EBC and plasma from healthy adults
We quantified thiocyanate in EBC and plasma acquired at the same visit from adult volunteers. Thiocyanate concentrations in EBC ranged from 12 to 60 nM, with a mean of 27 ± 16 nM (n = 7; Fig. 4) . Two additional EBC samples fell below the LLOQ and were not included in Fig. 1 the quantification. The concentrations estimated for these samples were 0.8 and 3.9 nM, respectively. A subset of samples were assayed three times over a 6-month period to determine reproducibility (Table 2) . Excluding one sample < LLOQ, the median inter-assay CV was 10.4% (n = 3). Plasma samples ranged from 27 to 90 µM thiocyanate with a mean of 46 ± 22 µM (n = 7; Fig. 4) . These values fall within previously reported ranges (Table 3 ). The median inter-assay CV of plasma samples measured three times over a 6-month period was 5.9% (n = 6). We also examined the association of thiocyanate concentrations in plasma with those of matched EBC samples from the same visit; however, a correlation between thiocyanate concentrations in the two compartments was not observed (data not shown).
Thiocyanate in BALF from infants with CF and mice
BALF samples acquired from the right middle lung lobes of 12-to 38-month-old CF patients were collected as part of a prospective study. BALF thiocyanate ranged from 0.2 to 5.8 µM with a mean value of 1.4 ± 1.4 µM (n = 24; Fig. 4 ). One additional sample was excluded as < LLOQ. BALF samples were measured only once, so reproducibility was not analyzed. We did not observe any statistically significant associations of thiocyanate with clinical data measured in this cohort, such as chest computed tomography-based PRAGMA-CF assessment of structural lung disease, current or past culture of microbes from BAL, or the proportions of BAL leukocytes (data not shown).
Mice are frequently used as model organisms for study of human disease, including airway diseases, such as CF [17] . Mouse BALF is derived from a lavage procedure of the whole lungs starting at the trachea, rather than lavage of a single lung lobe. We sought to compare the level of thiocyanate in mouse BALF to that recovered from patients using this method. Mouse BALF exhibited a similar concentration range to that of human BALF (0.3-1.3 µM), but exhibited less interindividual variance (mean=0.73 ± 0.39 µM; Fig. 4) , as expected for a model organism.
Discussion
Several recent clinical and animal studies have supported a link between thiocyanate and improvements in airway or cardiovascular health [7] [8] [9] [10] [11] . By enabling detection of low pmol amounts of thiocyanate, the method described in the current study will allow monitoring of thiocyanate in non-invasive clinical airways samples, such as EBC, thereby extending opportunities for research on airway thiocyanate. This method depends on the high mass accuracy and mass resolution of Orbitrap mass spectrometry to provide enhanced sensitivity (primarily via the removal of background noise), and is further aided by the sample-simplifying effect of headspace sampling. The results show that the method is not only suitable for EBC, but also BALF and plasma, with robust and reproducible quantification. This also demonstrated that underivatized thiocyanate in EBC and plasma is relatively stable at − 80°C and resistant to freeze-thaw effects.
Both EBC and BALF samples represent the distal airway lining fluid, but they differ greatly in collection method. Hence, different assumptions are required to correct for airway lining fluid dilution that occurs in the collection of both samples. For EBC, measurement of airway conductivity after ammonia removal gives results of approximately 2,000-fold [27, 28] . This suggests the EBC measurements in this study roughly correspond to 54 ± 32 µM in undiluted airway fluid. A major issue facing studies of EBC is the potential for saliva contamination [29] . Appropriate equipment for EBC collection such as RTubes divert salivary flow away from the sample; however, even trace contamination may cause problems, as saliva contains mM amounts of thiocyanate. Therefore, researchers measuring EBC thiocyanate should make every effort to include a dilution factor analysis and sensitive monitoring for salivary contamination. Unfortunately, insufficient sample was available to accomplish these goals in the current methoddeveloping study. For analysis of BALF, the ratio of urea to that in plasma or serum has been suggested as a dilution marker, but its validity has been repeatedly challenged [30] [31] [32] [33] . BALF has been roughly estimated as 100-fold diluted compared to undiluted epithelial lining fluid [18] , corresponding to a mean of 140 ± 140 µM thiocyanate in the CF BALF measured in this study. A previous study of 28 BALF samples from CF patients of comparable age found less than half as much thiocyanate than in the current study using an electrochemical detection method [18] . In another study, undiluted tracheal secretions in adults without respiratory disease had mean 460 µM thiocyanate, assayed by a ferric nitrate method [34] . Further studies are needed to better understand such large variations in lower airway thiocyanate, including rigorous approaches to dilution factor correction. The GC-HRMS method should allow facile systematic comparisons of thiocyanate in EBC, BALF and other airway samples, such as sputum. Sputum is a viscous sample containing large concentrations of mucins that may present additional analytical challenges not covered here. Thus, comparisons of sputum preparation methods, e.g., dithiothreitol or ethylenediaminetetraacetic acid-based methods, are advisable.
The concentration of thiocyanate in CF nasal lining fluid was strongly correlated with that of serum [8] . We tested if thiocyanate in EBC was correlated with thiocyanate in matched visit plasma from healthy adults and found no such relationship. This may reflect differences in the lining fluids of the upper and lower respiratory tracts or the small sample size in this study. Additional work will be required to address the possibility for equilibration or dynamic control of thiocyanate between blood and the airway lining fluids. Fig. 4 . Quantification of thiocyanate in biological fluids. GC-HRMS was applied to quantify SCN in matched EBC and plasma samples from healthy adults (n = 7) and BALF from children with cystic fibrosis (n = 24). For EBC and plasma samples measured more than once for reproducibility determination, the average value was used for plotting data. Mouse (C57BL/6) BALF was also assayed (n = 6). The y-axis gives SCN concentration (nM) on a log 10 scale and data are presented as Tukey boxplots. Two EBC samples were excluded from the graph for falling below LLOQ.
The origin of thiocyanate in the body is multi-factorial and includes several environmental factors such as high plant-based food intake and smoking [3, 4] . Thiocyanate is produced by rhodanese (i.e., thiosulfate sulfurtransferase) to detoxify cyanide, which is produced in the digestion of fruits and vegetables, is present in smoke, and can arise from bacterial metabolism [1, 35, 36] . In the current study, we were not poised to evaluate the effects of diet or smoking. In the CF patients, past or current infection did not impact thiocyanate, in agreement with previous findings [18] .
Interestingly, thiocyanate can be formed on protein cysteine residues following reaction with cyanide [37] . The current derivatization method should be selective for free thiocyanate, based on strong agreement with a minimal preparation ion chromatography method unlikely to break covalent bonds [24] . Covalently-bound thiocyanate makes up a small fraction of the total amount [38, 39] , but represents a distinct pathway for thiocyanate generation in vivo. In principle, the current method could be used to analyze bound thiocyanate after liberation from proteins [39] . Alternatively, specific S-cyanylated residues have been measured using mass spectrometry [37, 38] . Although free thiocyanate also engages in non-covalent interactions with biomolecules, isotopic equilibration of the internal standard during sample preparation controls for them.
In summary, we describe a GC-HRMS method for measurement of low nM amounts of thiocyanate. This enables facile measurement of thiocyanate in EBC, a non-invasive airway sampling method that produces a dilute sample. The method was validated for assay of samples stored at − 80°C for up to six months. The method is suitable for study of thiocyanate in airways of children with CF and other populations able to provide EBC samples. In addition to EBC, the method is also useful for the reliable quantification of thiocyanate in other clinical samples such as BALF and plasma. 
